Leerink Partners Downgrades Compass Therapeutics (NASDAQ:CMPX) to Market Perform

Leerink Partners cut shares of Compass Therapeutics (NASDAQ:CMPX) from an outperform rating to a market perform rating in a research report sent to investors on Friday, Marketbeat reports. They currently have $4.00 price target on the stock, down from their previous price target of $5.00.

Several other equities analysts have also issued reports on CMPX. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Compass Therapeutics in a report on Monday, November 11th. LADENBURG THALM/SH SH upgraded Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective for the company in a research note on Monday, September 16th. Finally, Wedbush reiterated an “outperform” rating and set a $8.00 target price on shares of Compass Therapeutics in a research note on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $6.75.

Compass Therapeutics Stock Down 13.2 %

NASDAQ:CMPX traded down $0.21 during trading hours on Friday, hitting $1.38. 1,348,934 shares of the company traded hands, compared to its average volume of 438,274. The company has a market cap of $189.87 million, a PE ratio of -3.73 and a beta of 0.92. The firm’s 50-day simple moving average is $1.75 and its 200-day simple moving average is $1.42. Compass Therapeutics has a one year low of $0.77 and a one year high of $2.34.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.03. As a group, equities research analysts expect that Compass Therapeutics will post -0.42 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of CMPX. Bleakley Financial Group LLC purchased a new position in Compass Therapeutics during the 1st quarter valued at about $80,000. Renaissance Technologies LLC grew its stake in Compass Therapeutics by 99.7% during the second quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock valued at $141,000 after acquiring an additional 70,200 shares in the last quarter. Rhumbline Advisers increased its holdings in Compass Therapeutics by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock worth $132,000 after acquiring an additional 12,315 shares during the period. Vanguard Group Inc. lifted its stake in Compass Therapeutics by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 4,152,197 shares of the company’s stock worth $8,221,000 after purchasing an additional 71,008 shares in the last quarter. Finally, Panagora Asset Management Inc. bought a new position in Compass Therapeutics in the 2nd quarter valued at $68,000. 68.43% of the stock is owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.